MA47502A - Combinaisons pharmaceutiques pour traiter le cancer - Google Patents
Combinaisons pharmaceutiques pour traiter le cancerInfo
- Publication number
- MA47502A MA47502A MA047502A MA47502A MA47502A MA 47502 A MA47502 A MA 47502A MA 047502 A MA047502 A MA 047502A MA 47502 A MA47502 A MA 47502A MA 47502 A MA47502 A MA 47502A
- Authority
- MA
- Morocco
- Prior art keywords
- treat cancer
- pharmaceutical combinations
- pharmaceutical
- combinations
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17020059 | 2017-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47502A true MA47502A (fr) | 2019-12-25 |
Family
ID=58108397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047502A MA47502A (fr) | 2017-02-20 | 2018-02-20 | Combinaisons pharmaceutiques pour traiter le cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20210187059A1 (fr) |
| EP (1) | EP3582804A1 (fr) |
| JP (1) | JP2020508315A (fr) |
| KR (1) | KR20190138633A (fr) |
| CN (1) | CN110603051A (fr) |
| AU (1) | AU2018221371A1 (fr) |
| BR (1) | BR112019017047A2 (fr) |
| CA (1) | CA3053857A1 (fr) |
| CL (1) | CL2019002325A1 (fr) |
| CO (1) | CO2019009000A2 (fr) |
| EA (1) | EA201991688A1 (fr) |
| IL (1) | IL268416B2 (fr) |
| MA (1) | MA47502A (fr) |
| MX (1) | MX2019009779A (fr) |
| PE (1) | PE20200149A1 (fr) |
| PH (1) | PH12019550138A1 (fr) |
| SG (1) | SG11201907217RA (fr) |
| UA (1) | UA126029C2 (fr) |
| WO (1) | WO2018149552A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI836643B (zh) | 2017-04-05 | 2024-03-21 | 哈佛大學校長及研究員協會 | 巨環化合物及其用途 |
| BR112020000141A2 (pt) | 2017-07-06 | 2020-07-14 | President And Fellows Of Harvard College | síntese de halicondrinas |
| US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
| CN111566113B (zh) | 2017-11-15 | 2024-01-09 | 哈佛大学的校长及成员们 | 大环化合物及其用途 |
| WO2022167157A1 (fr) * | 2021-02-05 | 2022-08-11 | Spexis Ag | Combinaisons d'éribuline-balixafortide pour le traitement du cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015012731A2 (pt) * | 2012-12-04 | 2017-07-11 | Eisai R&D Man Co Ltd | uso de eribulina no tratamento de câncer de mama |
| KR20170039096A (ko) * | 2014-05-28 | 2017-04-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료에 있어서 에리불린의 용도 |
-
2018
- 2018-02-20 EP EP18709923.9A patent/EP3582804A1/fr not_active Withdrawn
- 2018-02-20 UA UAA201909893A patent/UA126029C2/uk unknown
- 2018-02-20 MA MA047502A patent/MA47502A/fr unknown
- 2018-02-20 CA CA3053857A patent/CA3053857A1/fr active Pending
- 2018-02-20 WO PCT/EP2018/025042 patent/WO2018149552A1/fr active Application Filing
- 2018-02-20 BR BR112019017047A patent/BR112019017047A2/pt not_active IP Right Cessation
- 2018-02-20 MX MX2019009779A patent/MX2019009779A/es unknown
- 2018-02-20 SG SG11201907217RA patent/SG11201907217RA/en unknown
- 2018-02-20 AU AU2018221371A patent/AU2018221371A1/en not_active Abandoned
- 2018-02-20 PE PE2019001731A patent/PE20200149A1/es unknown
- 2018-02-20 US US16/486,945 patent/US20210187059A1/en not_active Abandoned
- 2018-02-20 JP JP2019545318A patent/JP2020508315A/ja active Pending
- 2018-02-20 CN CN201880012987.5A patent/CN110603051A/zh active Pending
- 2018-02-20 KR KR1020197027328A patent/KR20190138633A/ko not_active Application Discontinuation
- 2018-02-20 EA EA201991688A patent/EA201991688A1/ru unknown
-
2019
- 2019-08-01 IL IL268416A patent/IL268416B2/en unknown
- 2019-08-05 PH PH12019550138A patent/PH12019550138A1/en unknown
- 2019-08-16 CL CL2019002325A patent/CL2019002325A1/es unknown
- 2019-08-20 CO CONC2019/0009000A patent/CO2019009000A2/es unknown
-
2023
- 2023-04-05 US US18/296,104 patent/US20230381270A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UA126029C2 (uk) | 2022-08-03 |
| CN110603051A (zh) | 2019-12-20 |
| JP2020508315A (ja) | 2020-03-19 |
| CA3053857A1 (fr) | 2018-08-23 |
| MX2019009779A (es) | 2019-12-19 |
| US20210187059A1 (en) | 2021-06-24 |
| KR20190138633A (ko) | 2019-12-13 |
| CO2019009000A2 (es) | 2020-01-17 |
| BR112019017047A2 (pt) | 2020-04-28 |
| PE20200149A1 (es) | 2020-01-17 |
| IL268416A (en) | 2019-09-26 |
| AU2018221371A1 (en) | 2019-08-22 |
| EA201991688A1 (ru) | 2020-02-12 |
| IL268416B1 (en) | 2023-01-01 |
| SG11201907217RA (en) | 2019-09-27 |
| IL268416B2 (en) | 2023-05-01 |
| CL2019002325A1 (es) | 2020-05-15 |
| WO2018149552A1 (fr) | 2018-08-23 |
| EP3582804A1 (fr) | 2019-12-25 |
| US20230381270A1 (en) | 2023-11-30 |
| PH12019550138A1 (en) | 2020-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| DK3616720T3 (da) | Farmaceutisk sammensætning til cancerbehandling | |
| MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
| MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
| MA42420A (fr) | Vaccins pour le traitement et la prévention du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| BR112016027041A2 (pt) | Combinações farmacêuticas para tratamento do câncer | |
| ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
| MA50541A (fr) | Formulations pharmaceutiques | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| KR20180084772A (ko) | 암 치료를 위한 조합 치료법 | |
| MA47502A (fr) | Combinaisons pharmaceutiques pour traiter le cancer | |
| MA44874A (fr) | Thérapie génique pour traiter la mucopolysaccharidose de type ii | |
| MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| MA41555A (fr) | Polythérapie pour le traitement du cancer | |
| MA45406A (fr) | Inhibiteurs d'ezh2 pour traiter le cancer | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| MA45187A (fr) | Combinaisons pharmaceutiques | |
| MA54716A (fr) | Réduction de la viscosité de formulations pharmaceutiques | |
| MA47408A (fr) | Traitement du cancer | |
| MA46867A (fr) | Formulations pharmaceutiques | |
| MA40958A (fr) | Dispositifs de distribution de compositions pharmaceutiques topiques |